Needham & Company LLC reiterated their buy rating on shares of Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) in a report issued on Friday morning, Benzinga reports. The firm currently has a $26.00 target price on the stock. Separately, Stifel Nicolaus assumed coverage on shares of Phathom Pharmaceuticals in a research report on Friday. They set […]
Needham & Company LLC Reaffirms Buy Rating for Phathom Pharmaceuticals (NASDAQ:PHAT) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Comparing NeuroSense Therapeutics (NASDAQ:NRSN) and Phathom Pharmaceuticals (NASDAQ:PHAT) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report) will release its earnings data before the market opens on Thursday, May 9th. Analysts expect Phathom Pharmaceuticals to post earnings of ($1.13) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link. Phathom Pharmaceuticals (NASDAQ:PHAT – Get […]
Needham & Company LLC reiterated their buy rating on shares of Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) in a research note released on Friday, Benzinga reports. They currently have a $26.00 price target on the stock. Phathom Pharmaceuticals Stock Up 1.9 % PHAT stock opened at $9.35 on Friday. The stock has a market capitalization […]